Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC
Pasi A. Jänne, MD, PhD, discusses the rationale for exploring mobocertinib in EGFR exon 20–mutated non–small cell lung cancer.
EP: 1.Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC
EP: 2.Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer
EP: 3.Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP: 4.Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities
EP: 5.Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer
EP: 6.Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP: 7.Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC
EP: 8.Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC
EP: 9.Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC
EP: 10.Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC
EP: 11.Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
EP: 12.Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
Pasi A. Jänne, MD, PhD, a senior physician and director of the Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, and Chen-Huang Center for EGFR Mutant Lung Cancers at Dana-Farber Cancer Institute, discusses the rationale for exploring mobocertinib (formerly TAK-788) in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
Although prior EGFR inhibitors have been repurposed for use within this patient population, mobocertinib is a next-generation EGFR inhibitor that was preclinically designed to be more effective in patients whose tumors harbor EGFR exon 20 insertion mutations, according to Jänne.
This is a potential targeted therapy for patients with this subtype of EGFR-mutant NSCLC, says Jänne. Patients and providers alike should be optimistic about the data that have read out with emerging therapies like mobocertinib, as effective options for this population have been historically limited, Jänne concludes.
